Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

171
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
171
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

675
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
675
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.3K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.3K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.5K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service.

British journal of cancer·2026
Same author

NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer.

Journal of the National Cancer Institute·2025
Same author

Anticoagulation Practice and Risk of Portal Vein Thrombosis Following Pancreaticoduodenectomy or Total Pancreatectomy with Venous Resection: An International Multicentre Cohort Study.

Annals of surgery·2025
Same author

Improved glycaemic control in pancreatic diabetes mellitus following conversion from multiple daily insulin injections to continuous subcutaneous insulin infusion.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2025
Same author

Estimating treatment effects using parametric models as counter-factual evidence.

BMC medical research methodology·2025
Same journal

Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same journal

Machine learning model offers promising individualized prediction for recurrence-free survival in solitary resectable colorectal liver metastasis: strengths, limitations, and future directions.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same journal

Selective internal radiotherapy vs transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same journal

The impact of operative timing on major post-operative complications following liver transplantation: a retrospective cohort study.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same journal

Pancreatic resection for metastatic renal cell carcinoma: outcomes in the era of immunotherapy and targeted therapy.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same journal

Minimally Invasive Versus Open Surgery for Insulinoma: A 20-Year Institutional Experience.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
See all related articles

Related Experiment Videos

Adjuvant treatment.

Asma Sultana1, John Neoptolemos, Paula Ghaneh

  • 1Division of Surgery and Oncology, University of Liverpool, Liverpool, UK.

HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|March 12, 2008
PubMed
Summary
This summary is machine-generated.

Pancreatic ductal adenocarcinoma is a leading cause of cancer death. Adjuvant therapies are being developed to improve outcomes after surgery for this challenging cancer.

Related Experiment Videos

Area of Science:

  • Oncology
  • Gastroenterology
  • Surgical Oncology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer mortality globally.
  • Despite surgical resection, patient prognosis for PDAC remains poor.
  • There is a critical need for effective adjuvant therapies to improve survival rates.

Purpose of the Study:

  • To review major clinical trials investigating adjuvant therapies for pancreatic cancer.
  • To present the results of the ESPAC-1 trial.
  • To update on the ongoing status of the ESPAC-2 and ESPAC-3 trials.

Main Methods:

  • Review of key clinical trials on adjuvant chemotherapy and chemoradiotherapy for pancreatic cancer.
  • Analysis of the European Study Group for Pancreatic Cancer (ESPAC)-1 trial outcomes.
  • Summary of the current status of ESPAC-2 and ESPAC-3 trials.

Main Results:

  • The paper details various adjuvant treatment strategies including chemotherapy and chemoradiotherapy.
  • Specific results from the ESPAC-1 trial are presented.
  • The ongoing progress and design of ESPAC-2 and ESPAC-3 trials are discussed.

Conclusions:

  • Adjuvant therapies are crucial for improving outcomes in resected pancreatic cancer.
  • Ongoing trials like ESPAC-2 and ESPAC-3 are vital for establishing optimal adjuvant treatment regimens.
  • Further research is needed to enhance survival for patients with pancreatic ductal adenocarcinoma.